288 Fute Zhong Road
Waigaoqiao Free Trade Zone
70 articles with Wuxi Biologics
I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs
WuXi Biologics will also be the exclusive partner to develop and manufacture these bispecifics.
Revenue up 61.2% to a Record High of RMB1,054.4 Million.
Ligand Receives $47 Million from WuXi Biologics for Expansion of Worldwide OmniAb® Platform License Agreement
Updates 2018 Full Year and Second Quarter Financial Guidance
Brii Biosciences Launches with $260 Million, a Partnership with Vir Biotech, and Other Relationsh...
5/24/2018Brii Biosciences is launching to accelerate the development and delivery of breakthrough drugs in China with $260 million in financial backing.
Bioasis and WuXi Biologics Announce Initial Strategic Collaboration for the Development and Manufacturing of xB3-001, the Company’s Lead Investigational Candidate to Treat Brain Cancer
Bioasis will draw on WuXi Biologics’ expertise in developing complex biologic molecules for production of xB3-001 to support analytical development, formulation and IND-enabling in vivo studies
WuXi Biologics is to invest $392 million to build a new biologics drug substance manufacturing facility in Ireland.
WuXi Biologics to Install Industry’s Largest Single-Use Bioreactor from ABEC at its New Commercial Manufacturing Facility
Wuxi Biologics announced that it has selected 4,000 liter (L) Custom Single Run (CSR®) disposable bioreactors from ABEC for its new commercial manufacturing facility (MFG4) in Wuxi city, Jiangsu, China.
Aravive Biologics and WuXi Biologics to Form Strategic Manufacturing Collaboration Following Successful IND Filing for AVB-S6-500
Aravive Biologics and Wuxi Biologics (WuXi Bio, 02269.HK) today announced plans to expand their biologics manufacturing collaboration, based on the rapid success achieved in the process development, scale-up and cGMP manufacture of Aravive’s lead drug candidate, AVB-S6-500 (previously referred to as Aravive-S6).
Pfizer acquired China/Asia rights for Cresemba, an antifungal drug developed by Swiss pharma Basilea, in a $226M deal.
Completed in two stages, the plant has begun operating fourteen 2,000 liter disposable bioreactors for fed-batch cell culture in the facility.
The 3-year project aims to lower the cost of manufacturing mAbs significantly - to $5/g.
Ligand To Receive $2 Million From Wuxi Biologics For Licensing Clinical-Stage Anti-PD-1 Antibody Discovered Using The Omniab Technology
The U.S. FDA Completed Pre-License Inspection (PLI) Of Wuxi Biologics cGMP Manufacturing Facilities For Production Of TMB-355 (Ibalizumab)
EpimAb Biotherapeutics Collaborates With Wuxi Biologics To Advance Lead Bispecific Antibody Candidate Towards Clinical Development